The Unified Patent Court has found that Pfizer and BioNTech infringed GSK’s patent covering lipid-based RNA delivery technology used in their Comirnaty COVID-19 vaccine, granting an injunction spanning 35 European countries, subject to a three-month opportunity to agree a license.
GlaxoSmithKline (GSK) has secured a significant victory against Pfizer and BioNTech in a patent dispute concerning technology used in RNA vaccine delivery, after the Unified Patent Court (UPC) found that the pharmaceutical companies infringed European patent EP 2 590 626.
In a decision issued on November 10, 2026, the UPC’s Local Division in The Hague upheld the patent almost entirely, rejecting five principal validity challenges brought by Pfizer and BioNTech. However, the court revoked claim 13, relating to a medical use, for insufficient disclosure. The remaining claims survived the defendants’ validity attacks, and the court found that Pfizer and BioNTech’s Comirnaty COVID-19 vaccine infringed claims 1, 2, 3, 6, 10, and 12.
The patent, titled Liposomes with lipids having an advantageous pKa-value for RNA delivery, concerns lipid-based structures used to transport RNA into cells. These delivery systems are an important component of certain RNA vaccine technologies, enabling genetic material to enter cells and trigger an immune response. A central issue in the dispute concerned the patent’s claimed pKa range of 5.0 to 6.8. Pfizer and BioNTech challenged the patent’s validity on several grounds, including novelty and inventive step.
However, the court rejected the five principal invalidity attacks, finding that the defendants had not established that the relevant claimed subject matter lacked novelty or inventive step. The court also considered whether the ionizable lipid used in Comirnaty fell within the patent’s claimed pKa range. It concluded that the range could not be interpreted as having rigid cut-off points because the patent specification acknowledged a measurement uncertainty of approximately 0.2 pKa units.
Taking that tolerance into account, the court found that the lipid used in Comirnaty fell within the claimed range, supporting its finding of infringement.
Injunction could extend across 35 European countries
One of the most significant aspects of the judgment is the geographical reach of the injunction granted to GSK. The order covers 35 European countries in which the patent is valid, excluding the United Kingdom and Ireland. This includes the 18 participating UPC member states, seven additional EU member states, the Lugano Convention countries of Iceland, Norway and Switzerland, and other EPC contracting states, including Turkey.
The court relied on the UPC’s developing approach to long-arm jurisdiction, finding that the Pfizer and BioNTech groups operated through interdependent, integrated and centrally controlled corporate structures.
It concluded that the activities of the relevant companies could be attributed collectively, supporting the finding of joint infringement and the broad territorial scope of the order. However, the injunction will not take immediate effect. The court postponed enforcement until its decision becomes final and gave Pfizer and BioNTech three months from that point to secure a licensing agreement with GSK.
GSK must also provide the prescribed formal notice before enforcement. If the companies fail to agree to a license within the specified period, the injunction can become enforceable. For countries outside the UPC system, the order is additionally subject to conditions concerning the continued validity of the relevant national patent rights.
€2 million interim damages award
In addition to the infringement finding, the court ordered Pfizer and BioNTech to provide detailed information about their sales, prices, quantities and profits relating to the infringing products, dating back to January 1, 2020.
The defendants were also ordered to pay GSK an interim damages award of €2 million, with the final amount of compensation to be determined in separate proceedings.
The court set the value of the case at €50 million and ordered the defendants to pay GSK’s legal costs, including €1.75 million in agreed costs, in addition to court fees. Pfizer and BioNTech can appeal the decision, meaning the dispute is not necessarily over. The companies have also pursued parallel revocation proceedings against the patent in the United Kingdom and Ireland, which were excluded from the territorial scope of the UPC injunction.
Implications for pharmaceutical patent protection
The ruling represents an important development for pharmaceutical companies seeking to enforce patents covering technologies used in vaccine development and delivery. Beyond the specific dispute, the court’s approach to cross-border jurisdiction could have implications for future European patent litigation involving multinational pharmaceutical groups and interconnected manufacturing and distribution operations.
The conditional injunction is also noteworthy. Rather than requiring the immediate withdrawal of Comirnaty from the relevant markets, the court has provided an opportunity for the parties to negotiate a license, while preserving GSK’s ability to enforce its patent rights if an agreement cannot be reached.
For companies developing and commercializing mRNA-based medicines, the decision highlights the importance of assessing existing patent rights covering not only the genetic material itself but also the delivery technologies that enable these treatments to work. The judgment adds another significant chapter to the growing body of UPC case law concerning pharmaceutical patents, patent validity, joint infringement, and the territorial scope of injunctions.

Written by Elizabeth Jordan
Senior Industry Engagement Manager, CTC Legal Media
You may also like…
USPTO prepares to restore PTAB authority over patent challenges
The US Patent and Trademark Office (USPTO) is set to return responsibility for merits-based decisions on patent...
Netflix renews bid to suspend DivX patent injunction after EPO revocation
Netflix has made a second application to the Unified Patent Court (UPC) seeking to suspend an injunction obtained by...
Clarivate’s IPOne connects trusted patent, trademark, and litigation intelligence to Claude
New Derwent patent and Darts-ip litigation connections give IP professionals access to curated patent and litigation...
Contact us to write for out Newsletter











